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Introduction
The results of surgical resection of esophageal cancer have 
improved and mortality rate after esophagectomy is less 
than 5% in dedicated centers around the world. Long-term 
prognosis however remains suboptimal. Multimodality 
management strategies have been tested in order to 
improve outcome. Different regimens of multimodal 
therapies were explored in the last three decades involving 
pre- and post-operative chemotherapy and/or radiotherapy, 
with improved survival outcomes (1). Their adoption is 
widespread.
Since its publication in 2012, the Dutch Chemoradiotherapy 
for Oesophageal Cancer followed by Surgery Study 
(CROSS) has become a standard-of-care treatment for stage 
II and III esophageal cancer, both for squamous cell cancers 
and adenocarcinomas (2,3). It was a randomized controlled 
trial that involved 368 patients including both squamous 
and adenocarcinoma of the esophagus and gastroesophageal 
junction. Patients were randomized into either surgery 
alone group (188 patients) or chemoradiotherapy (weekly 
administration of carboplatin and paclitaxel with concurrent 
radiotherapy 41.4 Gy) followed by surgery (171 patients). 
The majority (75%) of patients had adenocarcinoma and 
the tumors were located either at the distal esophagus 
(58%) or esophagogastric junction (24%). The updated 
long-term results with a median follow-up for surviving 
patients of 84.1 months (range 61.1 to 116.8 months) 
showed that the median overall survival of the neoadjuvant 
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chemoradiotherapy group was 48.6 months and was 
24 months in the surgery alone group. The effect on 
squamous cell carcinomas was particularly impressive; the 
median overall survival for patients was 81.6 months in 
the neoadjuvant chemoradiotherapy plus surgery group 
and 21.1 months in the surgery alone group. Significant 
benefits were also found for patients with adenocarcinomas, 
median survival was 43.2 months in the neoadjuvant 
chemoradiotherapy plus surgery group and 27.1 months 
in the surgery alone group. Better control was found in 
both locoregional and distant disease progression. When 
translated to 5-year overall survival it was 47% versus 33% 
respectively. The update also provided additional data on 
median progression-free survival of 37.7 months in the 
neoadjuvant chemoradiotherapy group and 16.2 months in 
the surgery alone group. 
Other regimens are also used. In some countries, 
preoperative or peri-operative chemotherapy is preferred 
without addition of radiotherapy. In Japan, neoadjuvant 
chemotherapy with cisplatin and 5-fluourocil (5-FU) is the 
current standard in Japan, based on the randomized trial 
JCOG 9907, which compared preoperative vs. postoperative 
chemotherapy (4). In the United Kingdom, the MAGIC 
trial regimen is commonly used for adenocarcinoma 
of the gastroesophageal junction (5). Neoadjuvant 
chemoradiotherapy has also demonstrated a trend of 
survival advantage over neoadjuvant chemotherapy alone 
for adenocarcinomas of the esophagogastric junction in 
the German POET trial (6). Some on-going trials are 
eagerly anticipated; for squamous cell cancers, the NExT 
(JCOG 1009) study utilizes a three-group design compares 
conventional neoadjuvant cisplatin/5-FU regimen with 
intensified chemotherapy adding Docetaxel, and a third 
study group of concurrent radiotherapy with cisplatin 
and 5-FU (7). The Neo-AEGIS trial is a randomized trial 
of combined neoadjuvant and adjuvant chemotherapy 
(modi f ied  MAGIC regimen)  versus  neoadjuvant 
chemoradiation (CROSS) for adenocarcinoma of the 
esophagus and esophagogastric junction. This study 
includes 10 centers in Denmark, Ireland and United 
Kingdom, aiming to recruit 366 patients. The Neo-AEGIS 
Trial will have its estimated primary completion date in 
2024 (8).
Whatever regimen is used, neoadjuvant therapy aims at 
improving survival by tumor downstaging, increasing the chance 
of R0 resection with negative margins, and in theory also treat 
micrometastases. Such therapies (especially with radiotherapy) 
however, may have disadvantages. Patient’s physiological 
status may deteriorate after during chemoradiotherapy. 
They may become immunocompromised; radiotherapy 
may induce pneumonitis and cardiotoxicity. The fibrosis 
after radiotherapy may obscure tissue planes and may make 
surgery more challenging. Other surgical complications such 
as anastomotic leakage, recurrent laryngeal nerve injury are 
also reported to be more common after chemoradiotherapy, 
especially when surgery is carried out for salvage rather than 
in the neoadjuvant setting. A systemic review analysed pooled 
data from 954 patients in 8 studies, 712 patients underwent 
chemoradiotherapy with neoadjuvant intent and 242 had 
definitive chemoradiotherapy followed by salvage surgery. 
Morbidity and mortality rates were significantly higher in 
the salvage group (9). In CROSS, the in-hospital mortality 
rate was acceptable at 4%. Although there was no significant 
difference in the occurrence of postoperative complications 
between the two treatment groups, the actual incidence of 
anastomotic leaks was high at 22–30%. The authors did not 
give any postulation or explanation to this phenomenon. 
This figure is approaching the complication rate in salvage 
esophagectomy after radical chemoradiotherapy. From the 
Nationwide database in Japan of 5,354 patients in 2011, 
the anastomotic leakage rate was 13.3% and the thirty-day 
mortality rate was 1.2% (10). At the authors’ institution, 
post-operative morbidity and hospital mortality rates are 
comparable for multimodal therapy and upfront surgery. Our 
experience with neoadjuvant chemoradiotherapy in squamous 
cell carcinoma demonstrated significant tumor downstaging 
in 75% of patients, pathological complete response occurred 
in 31% (11). 
A significant minority of patients will not respond to 
neoadjuvant treatment with no added benefits or even 
harm as detailed above, and moreover surgical treatment is 
delayed. It is imperative that non-responders to treatment 
can be identified so that they are not exposed to potentially 
harmful chemoradiotherapy. Alternative strategies can be 
designed. 
Histopathological assessment of response to 
neoadjuvant therapy and prediction of survival 
outcome
There are different means of measuring tumor response to 
neoadjuvant therapy. Clinically the Response Evaluation 
Criteria in Solid Tumor (RECIST) criteria are often 
used, measured radiologically. Ultimately the definitive 
assessment will be by histopathology in patients whose 
tumors are resected. 
S775Journal of Thoracic Disease, Vol 9, Suppl 8 July 2017
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2017;9(Suppl 8):S773-S780jtd.amegroups.com
Mandard and associates investigated the pathological 
features of esophageal carcinoma in post-neoadjuvant 
chemoradiation esophagectomy specimens and were 
the first to report a prognostic classification using 
histopathological regression. They classified tumor 
regression into a scale of five, according to the degree of 
chemoradiation-induced fibrosis in relation to residual 
tumor cells (12). Schneider used a 4-category system of 
>50% vital residual tumor cells (VRTC), 10–50% VRTC, 
<10% VRTC, and 0% VRTC (13). The system by Chirieac 
classified responses into 0% residual tumor cells, 1-50% 
residual cells and more than 50% viable tumor cells (14). 
The classification by the Japanese Society for Esophageal 
Disease divided responses into class 0 as ineffective, class 
1 as slightly effective with viable cells more than one third 
of tumor tissue with evidence of degeneration, class 2 as 
moderately effective with viable cells less than one third of 
tumor tissue and severely degenerated, and class 3 which 
is markedly effective with no viable cells left (15) (Table 1). 
Pathological regression rate has prognostic value, and has 
been repeatedly shown by investigators (12,14,16). The 
authors have reported that on multivariate analysis in 175 
patients who had had neoadjuvant chemoradiotherapy 
followed by surgery, male gender, high percentage of 
residual viable tumor cells in the primary tumor, and 
positive nodal status were independent predictors of 
poor prognosis (11). In the literature, it has been shown 
consistently a good response to neoadjuvant therapies 
(especially pathological complete response pCR) is a 
favourable prognostic factor. 
Predictive markers of histopathological response 
to neoadjuvant therapy
For all of its advantages, neoadjuvant chemoradiotherapy is 
a double-edged sword. Good responders may have better 
survival in the long term, but in poor responders, disease 
may progress during the course of neoadjuvant treatment. 
There is thus an urgent need to identify accurate predictors 
of response, so that patients are not exposed to potentially 
harmful treatments without benefits, and management 
strategy can be modified accordingly. Much effort has been 
made in this regard. Clinical, biochemical and molecular 
predictors were identified for tumor regression after 
Table 1 Grading systems for primary tumor histopathological response to neoadjuvant therapy
Grading system Tumor grading Features of primary tumor
Mandard (12) 1 Complete response with fibrosis
2 Scatter viable cells and fibrosis
3 Increased number of viable cells but fibrosis still predominated
4 Amount of residual cells outgrowing fibrosis
5 Absence of regressive change
Schneider (13) 1 >50% vital residual tumor cells (VRTC)
2 10-50% VRTC
3 <10% VRTC
4 0% VRTC
Chirieac (14) 1 0% residual tumor cells
2 1-50% residual tumor cells
3 >50% residual tumor cells
Japanese Society of 
Esophageal Diseases 
(15)
0 Ineffective
1 Slightly effective: viable cells more than 1/3 of tumor tissue, but with evidence of degeneration
1a Viable cancer cells accounting for 2/3 or more tumor tissue
1b Viable cancer cells accounting for 1/3 or more, but less than 2/3, of tumor tissue
2 Moderately effective: viable cells less than 1/3 tumor tissue and severely degenerated or necrotic
3 Markedly effective: No viable cell
VRTC, Vital residual tumor cells.
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neoadjuvant therapy.
Clinical predictors
18F-f luorodeoxyglucose (18F-FDG)  positron emission 
tomography (PET) scans is widely used to stage esophageal 
cancer, and also to measure tumor activity. Standard uptake 
value (SUV) provides a measurement of viable tumor cell 
density. In a study by Ajani et al, post-chemoradiation SUV 
value of the primary tumor was an independent predictor of 
pathological complete response on multivariate analysis, in 
addition to several other clinical parameters (17). The study 
included both esophageal squamous cell carcinomas and 
adenocarcinomas. Female gender, well or moderate tumor 
differentiation, baseline T-stage by endoscopic ultrasound 
and absence of cancer cells on post-chemoradiation biopsies 
were positive predictors of pathological complete response. 
These factors were constructed into a normogram to 
predict pathological complete response. At a score of more 
than 160 points, the normogram predicted pCR with a 
probability of up to 60%, more reliably than any of the 
variables alone. Moreover, the pCR prediction normogram 
correlated with survival of patients who received definitive 
chemoradiotherapy (18). At the author’s institution, SUV 
value was also found to be a predictive factor. In 52 patients 
who had undergone neoadjuvant chemoradiotherapy and 
then surgical resection, 21 (40.4%) achieved pathological 
complete response (pCR). SUVmax of the primary tumor 
at one month post neoadjuvant therapy was independently 
predictive of pCR. However the predictive value was only 
modest, sensitivity was 71%, specificity was 66.7%, positive 
predictive value was 75.9%, and negative predictive value 
was 60.9% (19). 
A meta-analysis assessed 20 studies concluded that SUV 
response on FDG-PET was not accurate enough to predict 
tumor response to neoadjuvant chemoradiotherapy (20). 
Using more stringent criteria to include studies of higher 
quality, another meta-analysis included 13 studies, found that 
the pooled sensitivity, specificity, and diagnostic odds ratios 
for FDG-PET in the evaluation of neoadjuvant therapy 
response was 70.3%, 70.1% and 9.389 respectively (21). 
However the criteria for response based on PET and 
histopathological response were variable and therefore 
firm conclusions may not be entirely satisfactory. It was 
also interesting to note that studies of chemotherapy alone 
did not differ significantly compared with those with 
chemoradiotherapy, in spite of an expectation that radiation 
induced esophagitis and inflammation might be a possible 
confounding factor in PET assessment. 
The role of PET scan in early assessment of neoadjuvant 
response before the whole treatment is completed 
has been explored by some investigators. PET scan as 
early as two weeks into neoadjuvant chemotherapy was 
demonstrated to predict pathological complete response 
in adenocarcinomas of esophagus and esophagogastric 
junction. Its accuracy of prediction was similar to that 
of PET scan performed after completion of neoadjuvant 
therapy, perhaps implying steady histopathological response 
characteristics of adenocarcinomas (22). Similarly, a study 
was conducted in the context of squamous cell cancer 
of the esophagus. The absolute SUV levels at baseline 
and at two weeks into neoadjuvant chemoradiotherapy 
correlated with histopathological response. R0 resection 
and significantly better survival were achieved in patients 
with an SUV reduction of more than 30% (23). Then again 
the conclusion was drawn from a rather small number of 
patients. Whether this approach could be applied to predict 
pathological response at the early stage of neoadjuvant 
therapy for reliably needs to be elucidated in further studies.
Biochemical predictors
Blood parameters have been studied for prediction of tumor 
response to neoadjuvant therapy in esophageal and other 
cancers. Markers involved in inflammation and coagulation 
cascade appear to play a role in tumor progression but the 
precise mechanism is unclear.
Pre-treatment neutrophil-to-lymphocyte ratio (NLR) 
was proposed as a predictive marker for response to 
neoadjuvant chemotherapy in a Japanese study. Patients 
underwent the same neoadjuvant regime in the JCOG 
9907 trial and the majority had esophageal squamous cell 
cancers. An NLR of less than 2.2 was statistically associated 
with pathological response. The threshold for pathological 
response in this study was low however, at one-third 
disappearance of tumor cells (24). This is likely because of 
a low response rate to neoadjuvant chemotherapy in this 
study, with over 60% having less than one-third tumor cell 
disappearance, compared to previously reported figures (11).
Plasma fibrinogen is postulated by some to promote 
tumor progression by adherence of circulating tumor cells 
to the vasculature of distant organs, and was shown in 
several studies to be associated with tumor recurrence and 
metastases (25,26). It also influences integrin expression 
on endothelial cells and possibly modulates cellular 
pathways in tumor progression. One study showed that 
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a high pre-treatment plasma fibrinogen concentration, 
amongst other coagulative factors and acute phase proteins, 
was independently associated with good pathological 
response to neoadjuvant therapy. Eighty-four patients 
had either chemotherapy or chemoradiotherapy before 
surgical resection, the majority had adenocarcinoma (27). 
However this was contradicted by another Japanese study 
on esophageal squamous cell cancer patients treated with 
either upfront resection or radical chemoradiotherapy. 
Low pre-treatment plasma fibrinogen concentration was 
associated with complete response in a subgroup of stages 
II and III patients. Study patients however had definitive 
chemoradiation without surgery, therefore assessment of 
treatment response was based only on clinical grounds as 
resected specimens were not available. The selection criteria 
for treatment was also not clearly stated (26). Further 
investigations would be necessary to clarify the role and 
predictive value of fibrinogen.
The advantage of biochemical predictors is that they 
could be easily obtained from simple blood tests. No single 
marker however has been shown to be reliable so far.
Molecular predictors
With growing understanding of cancer genetics, certain genes 
appear to modulate tumor proliferation and chemotherapeutic 
drug metabolism. One of the most studied molecule is 
probably p53. It has been documented in the literature that 
p53, a tumor suppressor gene, enhances chemosensitivity. The 
exact mechanism of which p53 mediates neoadjuvant response 
awaits to be elucidated. A proposed mechanism theorizes 
that p53 mutation inhibits p73 that in turn mediates cellular 
apoptosis following Cisplatin exposure in head and neck 
squamous cell cancers (28).
Studies supported wild-type p53, identified from pre-
treatment endoscopic biopsies, as a good prognosticator 
for esophageal cancer patients who underwent neoadjuvant 
chemotherapy. In a meta-analysis examining the correlation 
between p53 status and response to chemotherapy-based 
treatment, wild-type p53 gene exhibited an association with 
pathological complete response in esophageal squamous 
cell cancer patients who were treated with neoadjuvant 
chemotherapy (29). However, in the experience of the 
authors’ institution, the correlation between pathological 
response and p53 expression was not as robust (30).
Low level of excision-repair cross-contemplating 1 
(ERCC1) mRNA expression has also been shown to link 
with superior response to Cisplatin-based chemotherapy in 
esophageal squamous cell cancers. It was demonstrated in 
a study that ERCC1 levels in esophageal squamous cancers 
with partial response to Cisplatin-based chemoradiotherapy 
were significantly lower than the levels in cancers without 
response, and that those with lower ERCC1 levels had 
greater sensitivity to platinum drugs (31).
Molecular processes in tumor biology are complex, 
pathways that are involved in cellular response to 
chemoradiotherapy are likely multistep and interlinked. 
Individual genes could pertain to only small fractions of the 
sequential cellular processes. This is a possible limitation 
in establishing single genes as predictors of response to 
neoadjuvant therapy. 
Microarray studies possibly resolve this problem. The merit 
of microarray expression analysis is that it simultaneously 
detects several genetic markers that are differentially 
expressed in the pre-treatment tumor biopsies of responders 
and non-responders. Using the medley of detected genetic 
markers, logistic regression models could be generated to 
predict pathological response. Two studies proposed such 
prediction models using several differentially expressed 
single-stranded non-coding microRNAs; miR-145-5p, 
miR-152, miR-193-3p and miR-376a-3p were used in one 
study (32), and MMP1, LIMCH1 and Clorf226 in another (33). 
Both looked at esophageal squamous cell cancer patients 
who underwent a standardized neoadjuvant regime, and the 
prediction models had high probabilities. A 32-gene classifier 
was identified in another study using complementary DNA 
microarray analysis of pre-treatment esophageal cancer 
biopsies. A mixed cohort of adenocarcinoma and squamous 
cell carcinomas was recruited, but when applied to squamous 
cell histology alone (21 samples) the proposed multi-gene 
model was capable of predicting pathological response (34). 
Although further studies are required to verify these models 
as their patient numbers were small, it is apparent that 
neoadjuvant treatment response is an interplay between 
several genes.
The aforementioned studies were conducted on pre-
treatment tumor biopsies. Recent studies have also 
demonstrated the predictive power of blood-based 
molecular markers. The pathological response prediction 
of ERCC1 was elicited in a study analysing pre-treatment 
serum samples of esophageal cancer patients who underwent 
Cisplatin-based neoadjuvant chemoradiation (35). A 
microarray study was conducted at the authors’ institution 
on peripheral blood samples of 20 esophageal squamous 
cell cancer patients who responded differently to Cisplatin- 
and 5-fluorouracil-based neoadjuvant chemoradiotherapy. 
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Responders were defined as those with 0% viable tumor 
cells in resected tissues from esophagectomy specimens, 
while those with at least 50% residual viable tumor cells 
were classified as non-responders. Upon validation in a 
larger set of responders and non-responders, MiR-193b in 
peripheral blood was shown to correlate significantly with 
response (unpublished data). These studies shed light onto 
circulating biomarkers as potential non-invasive tools for 
better patient selection for neoadjuvant therapy.
Thanks to the rapidly-growing field of molecular 
medicine, certain genes have evolved as potential response 
predictors. Albeit the optimism, molecular analysis is costly 
and labour intensive. Applying these biomarkers to clinical 
practice is not without hurdles.
Limitations of current studies on predictive 
markers for neoadjuvant response
Most of the studies were conducted on small samples of 
patients. Since responders and non-responders were defined 
differently, and the neoadjuvant regimes and tumor cell 
types were heterogenous in the studies, data could not 
be easily pooled for analysis. In addition, it is impossible 
to distinguish between spontaneous tumor necrosis and 
neoadjuvant therapy induced tumor necrosis histologically. 
The predictive power of the proposed markers may after 
all be over- or under-estimated. Stronger evidence is still 
needed to validate these methods of neoadjuvant response 
prediction. 
Response prediction and its implication on 
treatment for esophageal cancer
For  pa t i en t s  w i th  p red i c t ed  pCR,  neoad juvan t 
chemoradiotherapy is undoubtedly the treatment of choice. 
Much evidence has shown that those with pCR had better 
survival (36-39). How about patients with predicted subtotal 
pathological response? An unanswered question is, perhaps, 
what degree of histological tumor regression is required to 
bring upon a meaningful survival difference for patients. It 
is impossible to tell for the meantime, given the arbitrary 
definitions of pathological response used in current studies. 
In some studies, pathological responders were defined as 
pCR; in many others, it was defined in range of response 
percentages. This area will remain uncertain until this 
endpoint measurement is more clearly defined in future 
studies.
One of the latest areas of research is to test the concept 
of surveillance and salvage surgery only in the event of 
recurrence in predicted complete responders. This is 
being tested in an ongoing multicentre French trial (40). 
Another Dutch group is expected to conduct a randomized 
controlled trial (the SANO trial), to examine the safety of 
the same strategy, for those clinically assessed as complete 
responders. Prior to this trial, it has conducted a study 
to test the accuracy of clinical response evaluation in 
predicting pCR (the PreSANO study) (41). Study results 
are eagerly awaited.
Conclusions
Currently there is no reliable predictive marker of response 
to neoadjuvant chemoradiotherapy and is an active area 
for research. Continuing effort is required to fill the gaps 
of our understanding in the biology of chemoradiation 
response. Further studies are to be conducted to validate 
the potential markers, and to overcome problems of small 
sample size, non-standardized neoadjuvant regime and 
variable pathological response measurement. In the future, 
treatment for esophageal cancer hopefully will not only be 
individualized to disease stage and physical status of patients, 
but also be tailored to an accurately predicted response to 
chemoradiotherapy. The role of esophagectomy is evolving. 
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